Post hoc integrated analysis of two trials in 63 children with Alagille syndrome on maralixibat: over 96 weeks mean xanthoma scores fell, xanthoma-free prevalence rose from 60% to 86% (n=35 followed), and cholesterol and serum bile acids fell.
Secondary analysisn = 63
Hoskins et al. Maralixibat Improves Xanthomas and Hypercholesterolemia in Children with Alagille Syndrome: A Post Hoc Integrated Analysis From Two Clinical Trials